Search DIAN Data Resource Requests

In order to avoid the situation where two investigators study the same research question, please search our database to determine if your topic has already been studied. If you find that your topic or a related topic has already been submitted, you may wish to contact the investigator to inquire about his/her findings to determine how you might proceed. You may wish to collaborate or modify your request to avoid overlap. The results below reflect requests made since online requests have been accepted. As such, not all fields will have data as certain information, such as aims, were not collected until recently. If an entry has been assigned an ID # (e.g. DIAN-D1004), the full request has been submitted and is either approved, disapproved or in process.

Displaying 1 - 10 of 303

Investigator:Michael Ewers


Title:Analysis of proteomic signatures of MFG-E8 and medin amyloid in patients with autosomal dominant Alzheimer’s disease (ADAD)

Date of Request:07/21/2024

Status:pending approval

ID:DIAN-D2420




Aim 1:To test the association between MFG-E8 levels and neuroimaging markers of CAA




Aim 2:To test modulating factors of biofluid MFG-E8 levels including APOE e4 genotype and vascular risk factors




Aim 3:To determine the proteomic network and levels of medin associated with alterations in MFG-E8




Investigator:Francisco J. Martinez-Murcia


Title:Age of Onset determination in Autosomal Dominantly Inherited Alzheimer‘s Disease

Date of Request:07/09/2024

Status:pending approval

ID:DIAN-D2419




Aim 1:To inform a neuroimaging data-driven representation of AD progression that could be used to estimate the AoO of ADAD affected subjects.




Aim 2:To develop a deep latent variable model specifically targeted at modelling the fusion of neuroimaging data from different modalities







Investigator:Ellen Beard


Title:Investigating Personality Profiles in the Prediction of Dementia Clinical Presentation

Date of Request:07/05/2024

Status:pending approval

ID:DIAN-D2418




Aim 1:To explore whether personality profiles prior to dementia diagnosis predict subsequent behavioural and psychological symptoms of dementia










Investigator:Jorge J Llibre Guerra


Title:"Elucidating Protective Mechanisms in a PSEN1 Mutation Carrier Exhibiting Delayed Onset of Alzheimer's Disease"

Date of Request:07/03/2024

ID:DIAN- D2417




Aim 1:Investigate genetic variants contributing to the delayed onset of Alzheimer’s symptoms in a PSEN1 mutation carrier.




Aim 2:Analyze cross-sectional imaging and biomarker data to characterize disease progression and resilience mechanisms.




Aim 3:Identify and validate environmental factors contributing to the unique resilience observed in the individual.




Aim 4Develop comprehensive profiles for the proteomic and metabolomic alterations distinguishing the subject from typical DIAD mutation carriers.

Investigator:Randall Bateman


Title:Addendum to “Comparing biomarkers between Down Syndrome, Autosomal Dominant, and Late onset Alzheimer Disease.”

Date of Request:06/26/2024

Status:pending approval

ID:DIAN-D2416




Aim 1:Question 1a: How does the severity of white matter hyperintensities compare between DS and ADAD?




Aim 2:How does the presence of microbleeds compare across DS and ADAD?




Aim 3:Is enlarged perivascular space a common finding across DS and ADAD?




Aim 4Are the presence and progression of WMH, microbleeds, and PVS due to inflammatory processes?

Investigator:Mathias Jucker / Johannes Levin


Title:Is Maternal or Paternal origin of ADAD mutations relevant for clinical or biomarker outcome?

Date of Request:06/14/2024

Status:approved

ID:DIAN-D2415




Aim 1:Our aim is to determine whether the onset of Alzheimer's disease (AD) is affected by the inheritance pattern (paternal versus maternal) of AD-causing mutations.










Investigator:Wenqiang Fan


Title:Neuroinflammation Profiles in Alzheimer's Disease Patients with Distinct

Date of Request:06/03/2024

Status:pending approval

ID:DIAN-D2414




Aim 1:Overview the Landscape: Initially, we will assess the overall landscape of neuroinflammation across carriers of different risk variants.




Aim 2:Identify Unique Inflamed Cell Populations: We will then focus on identifying unique inflamed cell populations and compare the levels of inflammation across different risk variant carriers.




Aim 3:Evaluate Common Modulatory Factors: Finally, we will evaluate whether common factors can modulate neuroinflammation in various AD patients, potentially identifying targets for therapeutic intervention.




Investigator:Yuanyuan Lu


Title:Autosomal Dominant Alzheimer's Disease

Date of Request:05/26/2024

Status:pending

ID:DIAN-D2413




Aim 1:Investigate longitudinal patterns of clinical decline and neuroimaging changes in Autosomal Dominant Alzheimer's Disease.










Investigator:N/A


Title:Amyloid Chronicity in Autosomal Dominant Alzheimer’s Disease

Date of Request:05/23/2024

Status:approved

ID:DIAN-D2412




Aim 1:Examine associations between estimation of amyloid chronicity and Estimated Year of Symptom Onset (EYO) in Autosomal Dominant Alzheimer Disease




Aim 2:Compare longitudinal rate of amyloid accumulation across autosomal dominant Alzheimer Disease, sporadic Alzheimer Disease, and Down Syndrome




Aim 3:Determine the average length of time between becoming amyloid positive and cognitively impaired in different forms of Alzheimer Disease (autosomal dominant Alzheimer Disease, sporadic Alzheimer Disease, and Down Syndrome)




Investigator:David Cash


Title:Sample size estimates for biomarkers in prevention trials

Date of Request:04/17/2024

Status:approved

ID:DIAN-D2411




Aim 1:Assess the rate and variance of serial imaging measures in the Dominantly Inherited Alzheimer Network (DIAN) study




Aim 2:Compare sample size estimates from imaging outcomes with biofluid and cognitive measures




Aim 3:Assess the different power and design requirements for studies using different potential trial inclusion criteria (including but not limited to estimated years to onset, amyloid and tau positivity, cogntiive status) and suitable target treatment effects (reduced rate of atrophy/cognitive decline or reduction of absolute levels of AD-related pathology by end of study)




Aim 4Assess and compare the requirements for classical parallel arm trial design with more novel approaches (run-in designs, common close, staggered starts)

Displaying 1 - 10 of 303